References
- Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome. Science 1989; 244: 359–62
- Zakim D, Boyer TD. Hepatology. A textbook in liver disease. Saunders, Philadelphia 2003
- Veldhuijzen IK, Conijn-Van Spaendonck MAE, Dorigo-Zetsmab JW. Seroprevalentie van hepatitis B en C in de Nederlandse bevolking. Inf Ziekten Bull 2001; 10: 182–4
- Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35–46
- Farci P, Alter HJ, Shimoda A, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996; 335: 631–4
- Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Peters M, et al. Treatment of non-A non-B hepatitis with recombinant human alpha-interferon. A preliminary report. N Engl J Med 1986; 315: 1575–8
- Orlent H, Vrolijk JM, Veldt BJ, Schalm SW. Hepatitis C 2002 guidelines: summary and annotations. Scand J Gastroenterol 2003; 38:S239: 105–10
- McHutchison J, Davis GL, Esteban-Mur R, et al. Durability of sustained virological response in patients with chronic hepatitis C after treatment with interferon alpha-2b alone or in combination with ribavirin. Hepatology 2002; 35: 688–93
- Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65
- Fried MMW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82
- Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peg-interferon-(2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55
- Vrolijk JM, Bekkering FC, Brouwer JT, et al. High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy. J Viral Hepatol 2003; 10: 205–9
- Musselman DL, Lawson DH, Gummick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high dose interferon alpha. N Engl J Med 2001; 344: 961–6
- Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, et al. A prospective study of the incidence and open-label treatment interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942–7
- Bernstein D, Kleinman L, Barker CM, et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704–8
- Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 2491–9
- Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004; 126: 1302–11
- Narayana K, D'Souza UJ, Seetharama Rao KP. Ribavirin-induced sperm shape abnormalities in Wistar rat. Mutat Res 2002; 15;513: 193–6
- Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103–7
- Brouwer JT, Hansen BE, Niesters HG, Schalm SW. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999; 30: 192–8
- Lee S, Heathcote E, Reddy K, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002; 37: 500–6